WO1999011762A1 - An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine - Google Patents

An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine Download PDF

Info

Publication number
WO1999011762A1
WO1999011762A1 PCT/KR1998/000259 KR9800259W WO9911762A1 WO 1999011762 A1 WO1999011762 A1 WO 1999011762A1 KR 9800259 W KR9800259 W KR 9800259W WO 9911762 A1 WO9911762 A1 WO 9911762A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
vaccine
vero
japanese encephalitis
cell
Prior art date
Application number
PCT/KR1998/000259
Other languages
French (fr)
Inventor
Hyun Su Kim
Wang Don Yoo
Soo Ok Kim
Sung Hee Lee
Sang Bum Moon
Sun Pyo Hong
Yong Cheol Shin
Yong Ju Chung
Kenneth H. Eckels
Bruce Innis
Joseph R. Putnak
Leonard N. Binn
Ashok K. Srivastava
Doria R. Dubois
Original Assignee
Cheil Jedang Corporation
Walter Reed Army Institute Of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ503522A priority Critical patent/NZ503522A/en
Priority to DE122009000037C priority patent/DE122009000037I2/en
Priority to DE69837211T priority patent/DE69837211T2/en
Priority to JP2000508774A priority patent/JP4161017B2/en
Priority to AU90047/98A priority patent/AU748730B2/en
Priority to CA002301000A priority patent/CA2301000C/en
Application filed by Cheil Jedang Corporation, Walter Reed Army Institute Of Research filed Critical Cheil Jedang Corporation
Priority to US09/486,392 priority patent/US6309650B1/en
Priority to DK98941885T priority patent/DK1025209T3/en
Priority to EP98941885A priority patent/EP1025209B1/en
Publication of WO1999011762A1 publication Critical patent/WO1999011762A1/en
Priority to NL300391C priority patent/NL300391I2/en
Priority to FR09C0037C priority patent/FR09C0037I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell and a Japanese encephalitis vaccine comprising said attenuated virus.
  • Japanese encephalitis is a mosquito-borne arbo viral disease of major public health importance in Asia. More than 35,000 cases and 10,000 deaths are reported annually from that continent, but official reports undoubtedly underestimate the true number of cases (Okuno, T. World Health Stat Q. 3: 120-31,1978; Umenei, T. et al. Bull World Health Org. 63 : 625-31 , 1985).
  • the illness may be manifested by a febrile headache syndrome, aseptic meningitis, or encephalitis and about half of the survivors tend to have permanent neurologic and psychiatric sequelae (Burke, D.S. et al. The Arbovirus: Epidemiology and Ecology 3 :63-92, 1988; Monath, T.P. Virology 763-814, 1990).
  • JE virus is one of 66 Flaviviridae, enveloped, positive-sense, single stranded RNA viruses that largely are vector-borne (Chambers, T. J. et al. Ann. Rev. Microbiol. 44:649-88, 1990). Morphologically, flaviviruses are spherical, approximately 40 nm in diameter, are composed of a lipid bilayer surrounding a neucleocapsid containing 11 -kb genome complexed with a capsid (C) protein (Rice, C. M. et al. Science 229:726-33,
  • E glycosylated envelope
  • M membrane proteins.
  • Important physiological activities are associated with the 53-kd E protein, including hema- gglutination, viral neutralization, virion assembly, membrane fusion, and viral binding to cellular receptors (Koshini, E. et al. Virol. 188:714-20, 1992).
  • Inactivated JE vaccine produced in mouse brains was licensed in Japan in 1954.
  • Vero cells are transformed but non-tumorigenic cells derived from monkey kidney.
  • the Vero cell line is more advantageous than any other standard cell line in that Vero cells are more readily adaptable to large scale cell culture and as a transformed cell has an infinite life time.
  • JE virus can be grown in Vero cell culture. Considerable efforts had been made in the field of JE vaccine to produce vaccine in standard cells which permit effecting cell cultures at a large volume. Nevertheless, virus characterization including genetic stability, yield and process necessary for vaccine commercialization through cultivation with Vero cells had never met the requirements of human vaccine. Owing to these facts and to the difficulties of transposing a knowledge acquired in other virus cultures to JE virus, the prior art had not achieved success in the development of JE virus vaccine which is genetically stable and has a high immunogenic character from continuous cell lines. Among all these researches, none had resulted up to the present time in a new vaccine production which satisfies the criteria mentioned in this background.
  • the present invention suggests a development and a propagation of JE virus in continuous cell line, Vero cells for vaccine production which overcome previous problems in JE virus produced in mouse brain or primary cell lines.
  • the present invention also identifies methodology developed to cultivate the JE virus and a downstream process for vaccine production with cost-effectiveness.
  • the present invention identifies methodology improved upon the previously commercialized JE vaccines in the following ways.
  • the JE vaccine of the present invention is produced in the absence of bovine serum, making high yields and inexpensive and scalable production which are not achieved in the the previously commercialized JE vaccines.
  • an object of the present invention is to provide a safe and effective
  • a further object of the invention is to provide an effective process for producing a highly purified stable vaccine and formulating a vaccine which has a high immunogenic character with a small antigen amount.
  • the present invention provides an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.
  • the attenuated Japanese encephalitis virus of the present invention which is referred to as CJ50003 herein, was deposited at the permanent collection of the Korean Culture Center of Microorganisms, Seoul, Korea, on April 20, 1998 under the Budapest Treaty of the international recognition of the deposit of microorganisms for the purpose of patent procedure, and a subculture thereof can be obtained from the repository under the accession number
  • the present invention provides a Japanese encephalitis vaccine comprising an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.
  • Figure 1 shows passages and adaptation of JE virus SA14-14-2(PDK) in Vero cells.
  • Virus passage 1 was harvested at 5 days after inoculation of Vero cell monolayer with 0.1 moi of SA14-14-2(PDK) strain.
  • the JE virus titer was measured by plaque assay performed on Vero cell monolayers. Subsequent serial passages were conducted to 30 passages with virus passage 1 virus as starting material by successive virus infection and titration as described in Example 1.
  • Figure 2 shows multiple time harvest of JE virus C J50003 in a roller bottle every other day from 3 to 17 days post infection. Vero cell monolayer were infected at a moi of 0.01 plaque forming unit (pfu) per cell. Virus was allowed to adsorb for 2 hrs at
  • Figure 3 shows an analysis of JE virus CJ50003 purified by sucrose gradient ultracentrifugation by SDS-PAGE and Western blotting. Sixty ml of concentrated culture supernatant was applied to a forty ml of 15-60% sucrose gradient and centrifuged in a 45 Ti rotor at 22,000 rpm, 18 hrs., 12°C. Two ml samples were collected from the bottom of the tube and subjected to 4-20 % gradient SDS-PAGE and the resolved proteins were transferred to Nitrocellulose membranes.
  • Proteins were visualized by staining with Coomassie brilliant blue (Panel A) or silver nitrate (Panel B), and antigens were visualized by reaction with monoclonal antibody reactive against JE viral E protein (Panel C).
  • Lane 1 pre-stained protein standards (Novex SeeblueTM) representing molecular weights of 250, 98, 64, 50, 36, 30, 16, and 6 kDa from the top; Lane 2-10, fraction No. 3-11 from the bottom after ultracentrifugation; E, envelope protein; C, capsid protein; M, membrane protein.
  • Figure 4 shows formaldehyde inactivation kinetics of purified JE virus C J50003.
  • Purified JE virus preparations were inactivated with 0.018 % formaldehyde at 4°C or 22°C. Samples taken at the indicated times were titrated for their residual infectious virus by direct plaquing on Vero cell monolayers. Additionally, amplification assay was done to detect low levels of virus as follows. Duplicate flasks containing Vero cell monolayers were inoculated with samples from virus-inactivation time points. After a 2 hr adsorption period at 35 ° C, cells were refed and incubated at 35°C Cells were refed at 7 days and at 14 days post-infection.
  • the culture media were harvested and plaqued to detect infectious virus. Inactivation time points from two separate experiments are shown: 4 ° C (filled rectangle), 22 ° C (filled circle). Thermal inactivation (no formaldehyde) controls (open rectangle for 4 ° C and open circle for 22°C) were done in parallel.
  • the present invention relates to a JE virus strain which has desirable properties for the preparation of the JE vaccine.
  • Said virus is an attenuated virus and can propagate in the continuous cell line, Vero which is admitted by WHO as cell substrate for human vaccine production.
  • Vero which is admitted by WHO as cell substrate for human vaccine production.
  • said virus can be used for the preparation of more safe inactivated and live JE vaccines than current vaccines.
  • the present invention provides a vaccine that satisfies the present need.
  • a JE virus has been adapted to Vero cell by serial passages at no higher than 35 ° C Continued passages in Vero cell resulted in increase in virus titer, over 10 7 pfu per ml of culture supernatant and reduced culture time to show peak virus titer.
  • the invention concerns the development of a multiple time harvesting process with no serum requirement as supplement resulted in high yield of virus productivity, which is commercially feasible properties for the large-scale production of said vaccine with cost-effectiveness.
  • the multiple harvesting process in virus cultivation is responsible for the reduced degree of cytopathic effect (CPE) of infected cells.
  • CPE cytopathic effect
  • the JE vaccine of the present invention contains an extremely small quantity of residual cell derived components owing to the reduced level of CPE.
  • JE vaccine of the present invention is expected to afford enhanced immunogenicity and greater protection against disease than current JE vaccines.
  • the purified JE vaccine of the present invention has a major advantage over current vaccines in that the purified viruses from the cultured Vero cells meet the development requirements for human vaccine.
  • the present invention also relates to the methods for the preparation of said vaccine.
  • the methods can provide high productivity, purity and potency of said vaccine.
  • the JE virus CJ50003 is obtained by subjecting JE virus SA14-14-2(PDK) to 4 passages or more of adapting in the Vero tissue culture cells at temperatures no higher than 35°C and selecting the cultured virus while monitoring the virus propagation based on the number of foci which were formed in Vero and/or LLC-MK2 cells.
  • the virus obtained from that adaptation has a peak titer of at least lxl 0 7 pfu/ml of culture supernatant in Vero cell culture and reduced incubation period for harvest.
  • the JE virus SA14-14-2(PDK) to 4 passages or more of adapting in the Vero tissue culture cells at temperatures no higher than 35°C and selecting the cultured virus while monitoring the virus propagation based on the number of foci which were formed in Vero and/or LLC-MK2 cells.
  • the virus obtained from that adaptation has a peak titer of at least lxl 0 7 pfu/ml of culture supernatant in Vero cell
  • SA 14- 14-2 is an attenuated strain which is obtained by adapting a wild type JE virus
  • SA14-14-2(PDK) virus belongs to flaviviridae and has the following physicochemical properties: single-stranded, positive-sense RNA genome with 5' methylated end and 3' end with no poly A structure.
  • the size of RNA genome is approximately 11 kb and the genome is in a combined state with nucleocapsid (C) protein of 13,500 Da.
  • the virus is additionally comprised of membrane (M) protein of 8,700 Da, envelope (E) protein of 53,000 Da and non-structural proteins NS1, 2a, 2b, 3, 4a, 5 and the like.
  • the Vero adapted JE virus strain, CJ50003 was passed in Vero cell over 30 passages.
  • the virus titer and the morphology of plaque were not varied through passaging, suggesting that the virus has stable phenotypic character.
  • SA14-14-2(PDK) virus were replaced by three guanines and a thymine in JE CJ50003 virus, respectively. Accordingly, the amino acid sequence of E protein was changed from threonine of the 19 position, threonine of the 177 position, lysine of the 243 position and glutamine of the 264 position to alanine, alanine, glutamate and histidine, respectively. The amino acid changes on the E protein were maintained through passaging the virus in Vero cell as long as our investigation lasted.
  • the JE virus CJ50003 did not kill mice when the viruses which have different number of passages in Vero cells, were injected to young mice intracerebrally. Accordingly, it can be said that the Vero adapted JE virus CJ50003 is an attenuated and stable virus strain which has no or little neurovirulence. It is one of the critical points to use said virus for the live JE virus vaccine and/or inactivated vaccine.
  • the present invention also provides a method for purifying virus from cell culture without freezing the crude or interim purity materials.
  • Said method comprises the steps of removing cell debris, concentrating the virus, purifying the virus by precipitation of the materials of cell origin and sucrose gradient ultracentrifugation, fractionating the gradients and assaying the fractions for virus.
  • the present invention provides a method for the production of purified JE virus, by propagating virus to high titer in continuous cell lines, in the presence or absence of serum protein supplements, purifying the virus by ultracentrifugation, and pooling the virus-positive fractions.
  • the said virus is propagated in Vero tissue culture cells.
  • the confluently grown Vero cells in roller bottles are infected and incubated with the CJ50003 virus.
  • Harvesting the virus can be done by the multiple harvesting method.
  • the harvest of culture supernatant was started at the point of 2 or 3 days post infection according to moi of infection, and the fresh medium was refed to the culture. After 2 day incubation of the refed culture, the culture supernatant was harvested again.
  • Harvesting can be repeated up to 4 times by 8 or 9 days post infection with the virus titer maintained over 10 7 pfu/ml of culture supernatant.
  • the multiple harvesting method gave a high yield of virus per unit roller bottle, so it makes this invention more compatible with the laws of market.
  • the process is responsible for the reduced degree of CPE of infected cells.
  • the reduced level of CPE contributes to extremely low level of residual cell derived components in JE vaccine of the present invention.
  • the harvested culture supernatants can be stored at 4 ° C until the purification started.
  • the clarification of the harvested culture supernatants can be accomplished by common methods known in the art including low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45.
  • the harvested culture fluid is stored at 4°C until concentration. For the concentration of the virus, the culture fluid is ultrafiltrated and the retentate is collected.
  • the polyethylene glycol (PEG) 8000 is dissolved in the culture fluid up to 10% and the precipitate is dissolved in a proper buffer, for example phosphate-buffered saline (PBS, pH 7.0).
  • PBS phosphate-buffered saline
  • the protamine sulfate precipitation is performed for removing DNA or other materials which originated from the cell, which can be accomplished by addition of protamine sulfate to concentrated virus solution and high speed centrifugation, for example, at
  • fractions for virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as immunoassays.
  • the fractions for further processing are pooled on the basis of high virus titer and low level of other impurities. The purity of the pooled purified virus was estimated by testing for Vero cell originated chromosomal DNA and protein.
  • JE virus yield from 1 L of infected culture fluid is estimated to be about 2.3 milligrams.
  • the present invention also provides a method of inactivating JE virus to destroy its infectivity while preserving its antigenicity.
  • Said method comprises adding an effective quantity of formaldehyde and incubating said virus with said agent in certain conditions such that said virus is inactivated.
  • the fraction pool was diluted to appropriate protein concentration with a proper buffer such as PBS and the formaldehyde was added to the diluted fraction pool.
  • the incubation with formaldehyde was performed at 22°C or 4°C. At least 4 or 46 days were required to fully destroy viral infectivity without loss of viral antigenicity at 22°C or 4 ° C, respectively.
  • the inactivation process of JE virus at 22°C was preferably chosen for simplicity in large scale culture and incubation time was extended to 7 days for a safety margin.
  • examples of inactivating agents which were effective include but are not limited to formaldehyde. In general, this can be achieved by chemical or physical means. Chemical inactivation can be effected by treating the viruses, for example, with enzymes, ⁇ -propionlactone, ethylene-imine or a derivative thereof, and an organic solvent such as Tween, Triton, sodium deoxycholate, and sulphohetain. If necessary, the inactivating substance is neutralized afterwards; material inactivated with formaldehyde can, for example, be neutralized with thiosulphate.
  • Physical inactivation can preferably be carried out by subjecting the viruses to energy-rich radiation, such as UV light,
  • the JE vaccines are prepared as injectables, either as liquid solution or suspension. It is possible to add a stabilizing agent such as carbohydrates (sorbitol, mannitol, starch, sucrose, dextran, glucose, etc), proteins (albumins, casein, etc), an agent containing proteins (bovine serum, skim milk, etc) and buffers (such as alkali metal phosphate).
  • a stabilizing agent such as carbohydrates (sorbitol, mannitol, starch, sucrose, dextran, glucose, etc), proteins (albumins, casein, etc), an agent containing proteins (bovine serum, skim milk, etc) and buffers (such as alkali metal phosphate).
  • the preparation can be lyophilized after adding a stabilizer and it can be vacuum or nitrogen stored. If desired, one or more compounds with an adjuvant action can be added.
  • Suitable compounds for this purpose are, for example, aluminum hydroxide, phosphate or oxide, mineral oil (such as Bayol, Marcol 52) and saponins.
  • one or more emulsifiers, such as Tween and span, is also added to the virus materials.
  • the effectiveness of an adjuvant was determined by measuring the amount of neutralizing antibodies directed against the virus resulting from administration of the inactive virus in vaccines which are also absorbed to an adjuvant.
  • adjuvant which was effective include but is not limited to alum hydroxide.
  • the obtained vaccine was investigated for efficacy by the plaque reduction neutralization test (PRNT) with the sera of said vaccine immunized mice and direct challenge of immunized mice with a neurovirulent virus. As a result, it was shown that the said vaccine had the same as or better efficacy of eliciting neutralizing antibody than comparable vaccines.
  • PRNT plaque reduction neutralization test
  • the vaccines were prepared in different passage numbers and the efficacy of each vaccine was compared. There was no remarkable difference in efficacy among the vaccines prepared from viruses with different passage numbers in spite of successive passing in Vero cell. Thus it can be said that the Vero adapted JE virus strain, CJ50003, has stable immunogenicity.
  • JE S A 14- 14-2 (PDK) S A 14- 14-2 virus in dog kidney cell culture passage 8 was used to initiate serial passages in Vero cell culture.
  • the Vero cell monolayers were inoculated with JE SA14-14-2 (PDK) at an moi of 0.1 pfu per cell.
  • the infected cell cultures were grown in 25 cm 2 culture flasks containing 5 ml of nutrient media consisting of Eagle's minimal essential media supplemented with 10 % fetal bovine serum in an atmosphere of about 5 % CO 2 in air and at a temperature no higher than about 35 ° C, typically at from about 32 ° C to about 35 ° C, with about 35°C being preferred.
  • Viral growth was monitored by microscopic observation of cytopathic effect (CPE) and various assay for the presence of viral antigen including hemadsorption assay (HA), plaque assay, and enzyme linked immunoadsorbant assay (ELISA).
  • CPE cytopathic effect
  • HA hemadsorption assay
  • ELISA enzyme linked immunoadsorbant assay
  • JE virus was harvested at day 5 post infection when the culture showed peak of virus titer, clarified by centrifugation. The single plaque was purified from the clarified supernatant and amplified in Vero cells. The amplified virus was re-infected to Vero cell for further passages. Subsequent serial passages were conducted up to 30 passages by successive virus infection, titration, and plaque-purification as described above. As shown in
  • the virus titers reached about 4X10 7 pfu per ml of culture supernatant with 4 passages in Vero cells and maintained close to this level in further passages. Besides, the optimal period for viral harvest was reduced from 5 days at passage 1 to 2 - 3 days at passage 4. A significant increase in virus yield, about 10 5 pfu/rnl to over 10 7 pfu/ml and a decrease in incubation time resulted in the selection of the JE passage 4 in Vero cells as starting material of choice for the preparation of a candidate JE vaccine.
  • the JE passage 4 in Vero cells was labelled as CJ50003 (Vero, PS4).
  • Abbreviation PS means virus passage number in designated cell.
  • the 1500 nucleotide sequence encoding the envelope(E) gene which possesses major neutralizing epitopes were determined and compared with those of the parent vaccine strains, S A 14- 14-2(PDK), S A 14- 14-2(PHK) and an wild type SA14 virus (Aihira, S. et al. Virus Genes, 5:95-109, 1991; Ni, H. et al . J Gen Virol. 76:401-407, 1995; Ni, H. et al. J Gen Virol. 76:409-413, 1995; Nitayaphan, S. etal. Virology 177:541-542, 1990).
  • CJ50003 virus (Vero, PS4) was used for sequence analysis. This revealed that the C-terminal region (amino acid 280-500) shows complete conservation, while the N-terminal region (amino acid 1 -279) shows sequence variation among the virus strains. Mutations in the N-terminal region are almost evenly distributed. Nucleotide sequence of the E protein gene of CJ50003 differed from S A 14/CDC by 8 nucleotides and 7 amino acids whereas SA 14- 14-2(PDK) differed from SA14/CDC by 7 nucleotides and 5 amino acids. The results were summarized in Table 1.
  • CJ50003 virus differed from the published sequence of SA14- 14-2(PDK) virus at 5 positions: nucleotide changes at positions 1032, 1506, 1704 and 1769 resulted in 4 amino acid differences between SA14-14-2(PDK) and CJ50003 viruses: nucleotide changes at position 989 did not result in amino acid substitution.
  • Higher passages of CJ50003 virus, i.e. passage 15 and 30 revealed no additional nucleotide changes. There were, therefore 5 distinct nucleotide and 4 amino acid changes between CJ50003 and parent virus, SA14-14-2(PDK) and these changes were stable on passage of this virus in cell culture.
  • CJ50003 sequence also differed from the published sequence of SA14-14-2(PHK) virus (Aihira, S. etal. Virus Genes, 5:95-109, 1991).
  • the nucleotide difference at 1032 caused amino acid difference at position El 9 but the change at nucleotide position 989 did not result in amino acid substitution.
  • Nucleotides at 1506 and 1704 in CJ50003 virus were the same as those present in the SA14-14-2(PHK) at these positions while different from the SA14-14-2(PDK) at those positions.
  • the pattern of substitutions through the N-terminal region of the CJ50003 and SA14-14-2(PHK) E gene is almost same except for amino acid substitution at El 9.
  • SA14-14-2(PHK), SA14-14-2(PDK) and CJ50003 viruses have 4 identical amino acid substitutions compared with the sequence of the parent SA14 virus at position E107, E138, E176 and E279. Of those the amino acids at position E138 and E176 (Ni, H. et al. JGen Virol. 76:409-413, 1995), which were known to contribute to attenuation were still conserved after Vero adaptation, suggesting that CJ50003 did not lose it's attenuated character.
  • the volume of inoculum for i.e. injection is 0.03 ml per mouse.
  • Vero cell [CJ50003 (Vero, PS5)]and stored in deep-freezer.
  • Vero cells were grown in Eagle's minimal essential medium (EMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco).
  • EMEM Eagle's minimal essential medium
  • FBS fetal bovine serum
  • Roller bottle cultures of Vero cell monolayers were infected with production seed virus at an moi of 0.01 to 0.1 pfu per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM not containing serum and incubated at 35 ° C.
  • virus reached titers of around 10 7 to 10 8 pfu/ml at
  • virus titers were still maintained over 10 7 pfu/ml with very weak CPE. But after 9 days post infection, the titers were under 10 7 pfu/ml ( Figure 2).
  • the pooled harvests were centrifuged at 8,000 rpm for 15 minutes and supernatants were filtered through a 0.45 ⁇ m filter.
  • Virus culture supernatants were concentrated by ultrafiltration (Ultrasette, Filtron, 100k) or precipitation with PEG.
  • the virus precipitated by PEG was collected by centrifugation and suspended in PBS or STE (10 mM Tris pH 7.2, 1 mM EDTA, 150 mM NaCl) buffer. Retentate after ultrafiltration was concentrated to 250 ml and the cassette was washed with 100 ml of PBS. Virus concentrates were chilled in the ice for 2 hours after adding 0.5 -2 mg/ml of protamine sulfate and the supernatants obtained by centrifuging at 10,000 rpm for 5 minutes. The concentrated viruses were purified by ultracentrifugation on sucrose gradients. The ultracentrifugation was carried out at 38,000 g for 18 hours.
  • nucleocapsid protein C, 13,500 Da
  • membrane protein M, 8,700 Da
  • envelope protein E,
  • virus preparations were compared for relative purity using specific activity measurements (i.e., pfu/mg protein).
  • Virus purified from concentrate by ultrafiltration had about the same activity as virus purified from concentrate by PEG8000 precipitation.
  • purity of the pooled purified viruses was estimated by testing for Vero cell originated chromosomal DNA and protein. The results showed that contents of host cellular DNA and protein are as low as 2.5 pg and 2 ng per 5 ⁇ g of purified JE virus respectively regardless of method of concentration, which demonstrated that both purification methods described above effectively removed other impurities from viral antigen.
  • the purification method using ultrafiltration is 2-fold better than the purification method involving PEG8000 precipitation.
  • EXAMPLE 4 Virus inactivation Purified virus was either directly used for preparation of live attenuated vaccine after dialysis with PBS or inactivated with formaldehyde for preparation of inactivated vaccine. Inactivation with 0.018% formaldehyde was carried out at 22°C or 4 ° C. Samples were taken at regular intervals and assayed directly for infectious virus by plaque titration ( Figure 4). Samples which were negative by direct plaque assay were subjected to blind passage on Vero cell monolayers in order to amplify low levels of virus and then re-plaqued. It was found that 4 days at 22 ° C or 46 days at 4°C were required for complete inactivation of infectivity (Tables 5 and 6).
  • the antigenicity of the virus was monitored during inactivation by testing samples with the antigen spot blot assay and polyclonal antisera. By this assay there appeared to be no detectable losses in antigenicity after exposure to 0.018% formaldehyde for up to 10 days at 22°C or 15 days at 4°C.
  • Inactivation with formaldehyde under these conditions was carried out for at least 7 days at 22 ° C or 60 days at 4 ° C, giving a margin of safety. After inactivation, free formaldehyde in the samples was neutralized by the addition of 0.038% of sodium metabisulfite. Dialysis was carried out concurrently with PBS and then filtered through a 0.22 ⁇ m filter.
  • BBiikkeenn vvaacccciinnee b 11 ddoossee 1 320 a: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques . b: Biken vaccine 1 dose contains 5 ⁇ g of viral protein (TCA-precipitable) according to the manufacturer.
  • mice The Immunogenicity of PIV was further tested in mice.
  • Adult, inbred mice were immunized with various dilutions of inactivated virus with or without an alum adjuvant.
  • Groups of 20 six-week-old BALB/c mice were immunized subcutaneously with 500, 50, and 5 ng of PIV either in saline or saline with aluminum hydroxide (Rehydragel). Mice received two inoculations spaced 3 weeks apart.
  • Sera were pooled from each group of mice at 3 weeks post second immunization, and tested for the presence of neutralizing antibodies with mouse brain passaged Nakayana strain as neutralized virus (Table 8).
  • PIV was better than Biken vaccine in all doses and adjuvant significantly improved the immune response of mice to 50 and 500 ng of PIV about 4 and 8 fold, respectively.
  • Biken vaccine 1/1000 dose 1 10 a: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques, b: Biken vaccine 1 dose contains 5 ⁇ g of viral protein (TCA-precipi table) according to the manufacturer.
  • mice The in vivo protective efficacy of PIV was then tested in BALB/c mice.
  • groups of 10 three- week-old BALB/c mice were inoculated subcutaneously in the hindquarters with inactivated JE viruses in saline or saline with aluminum hydroxide (Rehydragel).
  • Age-matched controls were inoculated with PBS or non-specific antigens in alum.
  • Mice were boosted with an equivalent dose three weeks later.
  • the mice were challenged at 3 weeks post immunization by intracranial inoculation with 500 pfu of the mouse neurovirulent JE virus (Nakayama, mouse brain adapted) contained in 30 ⁇ l of PBS.
  • mice immunized with 50 ng of PIV showed 90% of protection.
  • mice immunized with 50 and 5 ng of PIV mixed with alum showed 100% and 70% protection, respectively while 1/100 dose of Biken vaccine protected just 50% of immunized mice. In comparison, all mice in the control group became sick and died beginning at five to seven days post-challenge.
  • Table 9 Protection of vaccinated mice against challenge with Nakayama virus 3 Immunogen
  • Biken vaccine 1/1000 dose 3/10 Mice immunized with 2 inoculations of test vaccines spaced 3 weeks apart, then challenged with 500 pfu of mouse-neuro virulent Nakayama virus, b: Age-matched controls were inoculated with PBS or non-specific antigens in alum c: Biken vaccine 1 dose contains 5 ⁇ g of viral protein (TCA-precipitable) according to the manufacturer .
  • PIV - 30ps 0.5 ⁇ g 1:160 13
  • a Immunogen (PIV -Xps); purified inactivated vaccine prepared with CJ50003 virus of which passage number in Vero cells is X.
  • b Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques and mean values of results from three separate experiments ere taken. 50% endpoint is determined by Reed and Muench method.
  • c Standard deviation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell and a Japanese encephalitis vaccine comprising said attenuated virus.

Description

AN ATTENUATED JAPANESE ENCEPHALITIS VIRUS
ADAPTED TO VERO CELL AND
A JAPANESE ENCEPHALITIS VACCINE
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell and a Japanese encephalitis vaccine comprising said attenuated virus.
DESCRIPTION OF THE PRIOR ART
Japanese encephalitis (JE) is a mosquito-borne arbo viral disease of major public health importance in Asia. More than 35,000 cases and 10,000 deaths are reported annually from that continent, but official reports undoubtedly underestimate the true number of cases (Okuno, T. World Health Stat Q. 3: 120-31,1978; Umenei, T. et al. Bull World Health Org. 63 : 625-31 , 1985). The illness may be manifested by a febrile headache syndrome, aseptic meningitis, or encephalitis and about half of the survivors tend to have permanent neurologic and psychiatric sequelae (Burke, D.S. et al. The Arbovirus: Epidemiology and Ecology 3 :63-92, 1988; Monath, T.P. Virology 763-814, 1990).
JE virus is one of 66 Flaviviridae, enveloped, positive-sense, single stranded RNA viruses that largely are vector-borne (Chambers, T. J. et al. Ann. Rev. Microbiol. 44:649-88, 1990). Morphologically, flaviviruses are spherical, approximately 40 nm in diameter, are composed of a lipid bilayer surrounding a neucleocapsid containing 11 -kb genome complexed with a capsid (C) protein (Rice, C. M. et al. Science 229:726-33,
1985). Surface projections on the membrane are composed of glycosylated envelope (E) and membrane (M) proteins. A pre-M glycoprotein, present in intracellular nascent virions, is cleaved to the M protein, found in mature extracellular virions. Important physiological activities are associated with the 53-kd E protein, including hema- gglutination, viral neutralization, virion assembly, membrane fusion, and viral binding to cellular receptors (Koshini, E. et al. Virol. 188:714-20, 1992).
There are three JE vaccines for humans (Tsai, T. et al. Vaccines 671 -713 , 1993). Of the three, only inactivated JE vaccine produced in mouse brain is available internationally. One manufacturer, the Research Foundation for Microbial Diseases of Osaka University (Biken) produces most of the inactivated JE vaccine distributed internationally; that vaccine was licensed in 1992 in the USA where it is distributed by Connaught Laboratories, Inc., as JE-VAX™. Inactivated and live attenuated JE vaccine prepared in primary hamster kidney (PHK) cells are distributed solely in China.
Inactivated JE vaccine produced in mouse brains was licensed in Japan in 1954.
Because it is produced by cerebral injection of infant mice, it is laborious to manufacture and concerns about the possibility of vaccine-related neurological side effect were raised. Though successive refinements in the manufacturing process have increased its purity and potency (Oya, A. Vaccination Theory and Practice 69-82, 1975; Oya, A. Acta Pediatr Jpn. 30:175-84, 1988; Takaku, K. Biken J. 11:25-39, 1968), a moderate frequency of local and mild systemic reactions have been reported until recently (Hoke, CH. et al. New EnglJ Med. 319:608-14, 1988; Poland, J.D. et al. J Infect Dis. 161:878-82, 1990; Sanchez, J.L. et al. Lancet 335:972-73, 1990). Local tenderness, redness, and/or swelling at the injection site occur in 20 % of vaccines. Mild systemic symptoms, chiefly headache, low-grade fever, myalgias, malaise, and gastrointestinal symptoms, are reported by 10 to 30 % of vaccines. An apparently new pattern of adverse reactions including urticaria, angioedema, respiratory distress, erythema multiforme, erythema nosodum and severe neurological disorders have been reported since 1989, principally among travellers vaccinated in Australia, Europe, and North America (Anderson, M.M. et al. Lancet.337:1044, 1991 ; Ruff, T. A. et al. Lancet
228:881-2, 1991). In addition, in 1992 and 1995 Ohtaki reported seven children with acute disseminated encephalomyelitis (ADEM) with changes on magnetic resonance images (MRI) after JE vaccination (Ohtaki, E. et al. Pediatr Neurol. 8:137-9, 1992; Ohtaki, E. et al. J Neurol Neurosurg Psychiatry 59:316-7, 1995). Also of note is that vaccination with rabies vaccine containing animal brain tissue has caused severe neurological complications (Plotkin, S.A. et al. Vaccines 661-2, 1994). For these reasons, the WHO has designated JE vaccine development as a high priority.
More recently, inactivated and live attenuated JE vaccine of China have proven to be effective, eliciting high titers of virus-neutralizing antibody and conferring solid protection (Tsai, T. et al. Vaccines 671-713, 1993). However, PHK cells in which
Chinese vaccine were prepared are not approved by the World Health Organization (WHO) for viral vaccine production or licensed for human use by the developed countries. The principal disadvantage in using primary hamster cells for the production of vaccines is the uncertainty with regard to the quality of vaccine. Even if specific pathogen free hamsters are used, animals can unexpectedly become infected, being problematic for vaccine production. Occasionally an infection of this type could be undetected for a long time. With these criticisms, further controlled studies of the safety of the vaccine are required to allow confidence regarding its widespread use. Another disadvantage of the vaccine production from primary cells is the low rate of harvest of the virus and high cost without allowing mass production.
In view of the above, there is a need for new JE vaccine which is produced in standard cell lines such as Vero or human diploid cells that have been accepted as human vaccine substrates, with good cost effectiveness. Vero cells are transformed but non-tumorigenic cells derived from monkey kidney. The Vero cell line is more advantageous than any other standard cell line in that Vero cells are more readily adaptable to large scale cell culture and as a transformed cell has an infinite life time.
It has now been found that JE virus can be grown in Vero cell culture. Considerable efforts had been made in the field of JE vaccine to produce vaccine in standard cells which permit effecting cell cultures at a large volume. Nevertheless, virus characterization including genetic stability, yield and process necessary for vaccine commercialization through cultivation with Vero cells had never met the requirements of human vaccine. Owing to these facts and to the difficulties of transposing a knowledge acquired in other virus cultures to JE virus, the prior art had not achieved success in the development of JE virus vaccine which is genetically stable and has a high immunogenic character from continuous cell lines. Among all these researches, none had resulted up to the present time in a new vaccine production which satisfies the criteria mentioned in this background.
The present invention suggests a development and a propagation of JE virus in continuous cell line, Vero cells for vaccine production which overcome previous problems in JE virus produced in mouse brain or primary cell lines. The present invention also identifies methodology developed to cultivate the JE virus and a downstream process for vaccine production with cost-effectiveness.
In addition, the present invention identifies methodology improved upon the previously commercialized JE vaccines in the following ways.
1. Safety: The invented virus did not acquire the virulence through the Vero cell cultivation, reducing the hazards of production and affording an additional level of safety to recipients beyond that furnished by stringent control over the virus-inactivation process. This advantage has never been provided by the previously commercialized JE vaccines.
2. Increased supply in safer production substrate: The JE vaccine of the present invention is produced in the absence of bovine serum, making high yields and inexpensive and scalable production which are not achieved in the the previously commercialized JE vaccines.
3. Less reactogenicity: No gelatin stabilizer is incorporated into the JE vaccine of the present invention, reducing the risk of vaccine reactions like those seen with the existing vaccine (Saskaguchi M. et al. Vaccines 68-69, 1998). In addition, undesirable bovine-derived components, incorporated in the existing JE vaccines are effectively eliminated. Conclusively, this safety point of the present invention has never been provided by the previous JE vaccine.
4. Increased potency: The success of scalable production with Vero cells and the absence of supplements for production, as well as the effective purification, permits the first use of potent adjuvants in formulating the JE vaccine. Although the use of the adjuvants in the vaccine formulation has been applied in other vaccine, transposing this knowledge to the JE vaccine has been in difficulty since none of the existing JE vaccines assure it's safe production.
In conclusion, none had resulted up to the present time in a new vaccine which satisfies the aforementioned advantages in the commercialization of JE vaccine.
Therefore, an object of the present invention is to provide a safe and effective
JE vaccine produced in standard cell substrate to increase its acceptability in many countries. A further object of the invention is to provide an effective process for producing a highly purified stable vaccine and formulating a vaccine which has a high immunogenic character with a small antigen amount.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.The attenuated Japanese encephalitis virus of the present invention, which is referred to as CJ50003 herein, was deposited at the permanent collection of the Korean Culture Center of Microorganisms, Seoul, Korea, on April 20, 1998 under the Budapest Treaty of the international recognition of the deposit of microorganisms for the purpose of patent procedure, and a subculture thereof can be obtained from the repository under the accession number
KCCM- 10125. In another aspect, the present invention provides a Japanese encephalitis vaccine comprising an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.
BRIEF DESCRIPTION OF THE DRAWINGS
These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying drawings as follows:
Figure 1 shows passages and adaptation of JE virus SA14-14-2(PDK) in Vero cells. Virus passage 1 was harvested at 5 days after inoculation of Vero cell monolayer with 0.1 moi of SA14-14-2(PDK) strain. The JE virus titer was measured by plaque assay performed on Vero cell monolayers. Subsequent serial passages were conducted to 30 passages with virus passage 1 virus as starting material by successive virus infection and titration as described in Example 1.
Figure 2 shows multiple time harvest of JE virus C J50003 in a roller bottle every other day from 3 to 17 days post infection. Vero cell monolayer were infected at a moi of 0.01 plaque forming unit (pfu) per cell. Virus was allowed to adsorb for 2 hrs at
35°C, then cells were washed with PBS three times, fed with 100 ml of serum-free EMEM and incubated at 35°C. Every 48 hrs from 3 days to 17 days post inoculation, culture supernatants were replaced with fresh serum-free EMEM. Virus infectivity titrations of the harvests were performed by plaquing on Vero-cell monolayers.
Figure 3 shows an analysis of JE virus CJ50003 purified by sucrose gradient ultracentrifugation by SDS-PAGE and Western blotting. Sixty ml of concentrated culture supernatant was applied to a forty ml of 15-60% sucrose gradient and centrifuged in a 45 Ti rotor at 22,000 rpm, 18 hrs., 12°C. Two ml samples were collected from the bottom of the tube and subjected to 4-20 % gradient SDS-PAGE and the resolved proteins were transferred to Nitrocellulose membranes. Proteins were visualized by staining with Coomassie brilliant blue (Panel A) or silver nitrate (Panel B), and antigens were visualized by reaction with monoclonal antibody reactive against JE viral E protein (Panel C). Lane 1, pre-stained protein standards (Novex Seeblue™) representing molecular weights of 250, 98, 64, 50, 36, 30, 16, and 6 kDa from the top; Lane 2-10, fraction No. 3-11 from the bottom after ultracentrifugation; E, envelope protein; C, capsid protein; M, membrane protein.
Figure 4 shows formaldehyde inactivation kinetics of purified JE virus C J50003. Purified JE virus preparations were inactivated with 0.018 % formaldehyde at 4°C or 22°C. Samples taken at the indicated times were titrated for their residual infectious virus by direct plaquing on Vero cell monolayers. Additionally, amplification assay was done to detect low levels of virus as follows. Duplicate flasks containing Vero cell monolayers were inoculated with samples from virus-inactivation time points. After a 2 hr adsorption period at 35°C, cells were refed and incubated at 35°C Cells were refed at 7 days and at 14 days post-infection. The culture media were harvested and plaqued to detect infectious virus. Inactivation time points from two separate experiments are shown: 4°C (filled rectangle), 22°C (filled circle). Thermal inactivation (no formaldehyde) controls (open rectangle for 4°C and open circle for 22°C) were done in parallel.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a JE virus strain which has desirable properties for the preparation of the JE vaccine. Said virus is an attenuated virus and can propagate in the continuous cell line, Vero which is admitted by WHO as cell substrate for human vaccine production. Thus it is expected that said virus can be used for the preparation of more safe inactivated and live JE vaccines than current vaccines.
The present invention provides a vaccine that satisfies the present need. A JE virus has been adapted to Vero cell by serial passages at no higher than 35°C Continued passages in Vero cell resulted in increase in virus titer, over 107 pfu per ml of culture supernatant and reduced culture time to show peak virus titer. The invention concerns the development of a multiple time harvesting process with no serum requirement as supplement resulted in high yield of virus productivity, which is commercially feasible properties for the large-scale production of said vaccine with cost-effectiveness. According to the invention, the multiple harvesting process in virus cultivation is responsible for the reduced degree of cytopathic effect (CPE) of infected cells. The JE vaccine of the present invention contains an extremely small quantity of residual cell derived components owing to the reduced level of CPE. In addition, JE vaccine of the present invention is expected to afford enhanced immunogenicity and greater protection against disease than current JE vaccines. The purified JE vaccine of the present invention has a major advantage over current vaccines in that the purified viruses from the cultured Vero cells meet the development requirements for human vaccine.
The present invention also relates to the methods for the preparation of said vaccine. The methods can provide high productivity, purity and potency of said vaccine.
The JE virus CJ50003 is obtained by subjecting JE virus SA14-14-2(PDK) to 4 passages or more of adapting in the Vero tissue culture cells at temperatures no higher than 35°C and selecting the cultured virus while monitoring the virus propagation based on the number of foci which were formed in Vero and/or LLC-MK2 cells. The virus obtained from that adaptation has a peak titer of at least lxl 07 pfu/ml of culture supernatant in Vero cell culture and reduced incubation period for harvest. The JE virus
SA 14- 14-2 is an attenuated strain which is obtained by adapting a wild type JE virus
SA14 from mosquito in the Primary Hamster Kidney (PHK) tissue culture cell and the
Primary Dog Kidney (PDK) tissue culture cell (Kenneth H. Eckels, et al. Vaccine 6513- 518, 1988). But the PHK and PDK cells are not admitted by WHO, so they are not suitable for preparation of vaccines applicable to humans. The Vero cell is admitted by
WHO for human use, so the Vero adapted JE virus strain, CJ50003, is a good basis for production of vaccine for humans.
It is known that SA14-14-2(PDK) virus belongs to flaviviridae and has the following physicochemical properties: single-stranded, positive-sense RNA genome with 5' methylated end and 3' end with no poly A structure. The size of RNA genome is approximately 11 kb and the genome is in a combined state with nucleocapsid (C) protein of 13,500 Da. The virus is additionally comprised of membrane (M) protein of 8,700 Da, envelope (E) protein of 53,000 Da and non-structural proteins NS1, 2a, 2b, 3, 4a, 5 and the like.
The Vero adapted JE virus strain, CJ50003 was passed in Vero cell over 30 passages. The virus titer and the morphology of plaque were not varied through passaging, suggesting that the virus has stable phenotypic character.
To get an insight into the molecular basis for the biological characteristics of JE virus CJ50003, the physicochemical properties of the virus were analyzed. The sequence of the bases of the viral genome was determined by cDNA cloning and sequencing. As a result, it was discovered that three adenine bases of the 1032, 1506, and 1704 positions, and a guanine base of the 1769 position of E protein gene of JE
SA14-14-2(PDK) virus were replaced by three guanines and a thymine in JE CJ50003 virus, respectively. Accordingly, the amino acid sequence of E protein was changed from threonine of the 19 position, threonine of the 177 position, lysine of the 243 position and glutamine of the 264 position to alanine, alanine, glutamate and histidine, respectively. The amino acid changes on the E protein were maintained through passaging the virus in Vero cell as long as our investigation lasted.
The JE virus CJ50003 did not kill mice when the viruses which have different number of passages in Vero cells, were injected to young mice intracerebrally. Accordingly, it can be said that the Vero adapted JE virus CJ50003 is an attenuated and stable virus strain which has no or little neurovirulence. It is one of the critical points to use said virus for the live JE virus vaccine and/or inactivated vaccine.
The present invention also provides a method for purifying virus from cell culture without freezing the crude or interim purity materials. Said method comprises the steps of removing cell debris, concentrating the virus, purifying the virus by precipitation of the materials of cell origin and sucrose gradient ultracentrifugation, fractionating the gradients and assaying the fractions for virus. More specifically, the present invention provides a method for the production of purified JE virus, by propagating virus to high titer in continuous cell lines, in the presence or absence of serum protein supplements, purifying the virus by ultracentrifugation, and pooling the virus-positive fractions.
The said virus is propagated in Vero tissue culture cells. The confluently grown Vero cells in roller bottles are infected and incubated with the CJ50003 virus. Harvesting the virus can be done by the multiple harvesting method. The harvest of culture supernatant was started at the point of 2 or 3 days post infection according to moi of infection, and the fresh medium was refed to the culture. After 2 day incubation of the refed culture, the culture supernatant was harvested again. Harvesting can be repeated up to 4 times by 8 or 9 days post infection with the virus titer maintained over 107 pfu/ml of culture supernatant. The multiple harvesting method gave a high yield of virus per unit roller bottle, so it makes this invention more compatible with the laws of market. Furthermore, the process is responsible for the reduced degree of CPE of infected cells. The reduced level of CPE contributes to extremely low level of residual cell derived components in JE vaccine of the present invention. The harvested culture supernatants can be stored at 4°C until the purification started. The clarification of the harvested culture supernatants can be accomplished by common methods known in the art including low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45. The harvested culture fluid is stored at 4°C until concentration. For the concentration of the virus, the culture fluid is ultrafiltrated and the retentate is collected. In another method for concentration, the polyethylene glycol (PEG) 8000 is dissolved in the culture fluid up to 10% and the precipitate is dissolved in a proper buffer, for example phosphate-buffered saline (PBS, pH 7.0). The protamine sulfate precipitation is performed for removing DNA or other materials which originated from the cell, which can be accomplished by addition of protamine sulfate to concentrated virus solution and high speed centrifugation, for example, at
12,000 g, for 5 min. For further purification of the virus, density gradient ultracentrifugation is performed on 15-60% continuous or multi-step sucrose gradients. The sucrose gradient is fractionated and the fractions are assayed for the virus. Methods for assaying for virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as immunoassays. The fractions for further processing are pooled on the basis of high virus titer and low level of other impurities. The purity of the pooled purified virus was estimated by testing for Vero cell originated chromosomal DNA and protein. The results showed that contents of host cellular DNA and protein are as low as 2.5 pg and 2 ng per 5 μg of purified JE virus, respectively, which demonstrated the purification methods described above effectively removed other impurities from viral antigen. JE virus yield from 1 L of infected culture fluid is estimated to be about 2.3 milligrams.
The present invention also provides a method of inactivating JE virus to destroy its infectivity while preserving its antigenicity. Said method comprises adding an effective quantity of formaldehyde and incubating said virus with said agent in certain conditions such that said virus is inactivated. Specifically, the fraction pool was diluted to appropriate protein concentration with a proper buffer such as PBS and the formaldehyde was added to the diluted fraction pool. The incubation with formaldehyde was performed at 22°C or 4°C. At least 4 or 46 days were required to fully destroy viral infectivity without loss of viral antigenicity at 22°C or 4°C, respectively. The inactivation process of JE virus at 22°C was preferably chosen for simplicity in large scale culture and incubation time was extended to 7 days for a safety margin. However, examples of inactivating agents which were effective include but are not limited to formaldehyde. In general, this can be achieved by chemical or physical means. Chemical inactivation can be effected by treating the viruses, for example, with enzymes, β-propionlactone, ethylene-imine or a derivative thereof, and an organic solvent such as Tween, Triton, sodium deoxycholate, and sulphohetain. If necessary, the inactivating substance is neutralized afterwards; material inactivated with formaldehyde can, for example, be neutralized with thiosulphate. Physical inactivation can preferably be carried out by subjecting the viruses to energy-rich radiation, such as UV light,
X-radiation or gamma-radiation. The JE vaccines are prepared as injectables, either as liquid solution or suspension. It is possible to add a stabilizing agent such as carbohydrates (sorbitol, mannitol, starch, sucrose, dextran, glucose, etc), proteins (albumins, casein, etc), an agent containing proteins (bovine serum, skim milk, etc) and buffers (such as alkali metal phosphate). The preparation can be lyophilized after adding a stabilizer and it can be vacuum or nitrogen stored. If desired, one or more compounds with an adjuvant action can be added. Suitable compounds for this purpose are, for example, aluminum hydroxide, phosphate or oxide, mineral oil (such as Bayol, Marcol 52) and saponins. In addition, if desired, one or more emulsifiers, such as Tween and span, is also added to the virus materials.
The effectiveness of an adjuvant was determined by measuring the amount of neutralizing antibodies directed against the virus resulting from administration of the inactive virus in vaccines which are also absorbed to an adjuvant. Examples of adjuvant which was effective include but is not limited to alum hydroxide. The obtained vaccine was investigated for efficacy by the plaque reduction neutralization test (PRNT) with the sera of said vaccine immunized mice and direct challenge of immunized mice with a neurovirulent virus. As a result, it was shown that the said vaccine had the same as or better efficacy of eliciting neutralizing antibody than comparable vaccines.
To investigate possible changes in immunogenicity of Vero adapted viruses with different passage numbers, the vaccines were prepared in different passage numbers and the efficacy of each vaccine was compared. There was no remarkable difference in efficacy among the vaccines prepared from viruses with different passage numbers in spite of successive passing in Vero cell. Thus it can be said that the Vero adapted JE virus strain, CJ50003, has stable immunogenicity.
The following examples illustrate the attenuated JE virus adapted to Vero cell according to the present invention and the JE vaccine comprising said attenuated virus according to the present invention. From the foregoing description and the following examples, it is believed that those skilled in the art would be able to carry out the invention to the fullest extent.
EXAMPLE 1
Adaptation of SA14-14-2(PDK) virus in Vero cell
JE S A 14- 14-2 (PDK), S A 14- 14-2 virus in dog kidney cell culture passage 8 was used to initiate serial passages in Vero cell culture. The Vero cell monolayers were inoculated with JE SA14-14-2 (PDK) at an moi of 0.1 pfu per cell. The infected cell cultures were grown in 25 cm2 culture flasks containing 5 ml of nutrient media consisting of Eagle's minimal essential media supplemented with 10 % fetal bovine serum in an atmosphere of about 5 % CO2 in air and at a temperature no higher than about 35°C, typically at from about 32°C to about 35°C, with about 35°C being preferred. Viral growth was monitored by microscopic observation of cytopathic effect (CPE) and various assay for the presence of viral antigen including hemadsorption assay (HA), plaque assay, and enzyme linked immunoadsorbant assay (ELISA). JE virus was harvested at day 5 post infection when the culture showed peak of virus titer, clarified by centrifugation. The single plaque was purified from the clarified supernatant and amplified in Vero cells. The amplified virus was re-infected to Vero cell for further passages. Subsequent serial passages were conducted up to 30 passages by successive virus infection, titration, and plaque-purification as described above. As shown in
Figure 1, the virus titers reached about 4X107 pfu per ml of culture supernatant with 4 passages in Vero cells and maintained close to this level in further passages. Besides, the optimal period for viral harvest was reduced from 5 days at passage 1 to 2 - 3 days at passage 4. A significant increase in virus yield, about 105 pfu/rnl to over 107 pfu/ml and a decrease in incubation time resulted in the selection of the JE passage 4 in Vero cells as starting material of choice for the preparation of a candidate JE vaccine. The JE passage 4 in Vero cells was labelled as CJ50003 (Vero, PS4). Abbreviation PS means virus passage number in designated cell.
EXAMPLE 2
Characterization of CJ50003 virus; Sequencing of the envelope gene and neurovirulence study
As an effort to give an insight into the molecular basis for the biological characteristic of CJ50003 strain, the 1500 nucleotide sequence encoding the envelope(E) gene which possesses major neutralizing epitopes were determined and compared with those of the parent vaccine strains, S A 14- 14-2(PDK), S A 14- 14-2(PHK) and an wild type SA14 virus (Aihira, S. et al. Virus Genes, 5:95-109, 1991; Ni, H. et al . J Gen Virol. 76:401-407, 1995; Ni, H. et al. J Gen Virol. 76:409-413, 1995; Nitayaphan, S. etal. Virology 177:541-542, 1990). CJ50003 virus (Vero, PS4) was used for sequence analysis. This revealed that the C-terminal region (amino acid 280-500) shows complete conservation, while the N-terminal region (amino acid 1 -279) shows sequence variation among the virus strains. Mutations in the N-terminal region are almost evenly distributed. Nucleotide sequence of the E protein gene of CJ50003 differed from S A 14/CDC by 8 nucleotides and 7 amino acids whereas SA 14- 14-2(PDK) differed from SA14/CDC by 7 nucleotides and 5 amino acids. The results were summarized in Table 1.
The sequence of CJ50003 virus differed from the published sequence of SA14- 14-2(PDK) virus at 5 positions: nucleotide changes at positions 1032, 1506, 1704 and 1769 resulted in 4 amino acid differences between SA14-14-2(PDK) and CJ50003 viruses: nucleotide changes at position 989 did not result in amino acid substitution. Higher passages of CJ50003 virus, i.e. passage 15 and 30 revealed no additional nucleotide changes. There were, therefore 5 distinct nucleotide and 4 amino acid changes between CJ50003 and parent virus, SA14-14-2(PDK) and these changes were stable on passage of this virus in cell culture. The Lys residue at 243 in the
SA14-14-2(PDK), which is uniquely different compared with other attenuated JE viruses were substituted with Glu residue in CJ50003.
CJ50003 sequence also differed from the published sequence of SA14-14-2(PHK) virus (Aihira, S. etal. Virus Genes, 5:95-109, 1991). The nucleotide difference at 1032 caused amino acid difference at position El 9 but the change at nucleotide position 989 did not result in amino acid substitution. Nucleotides at 1506 and 1704 in CJ50003 virus were the same as those present in the SA14-14-2(PHK) at these positions while different from the SA14-14-2(PDK) at those positions. The pattern of substitutions through the N-terminal region of the CJ50003 and SA14-14-2(PHK) E gene is almost same except for amino acid substitution at El 9.
SA14-14-2(PHK), SA14-14-2(PDK) and CJ50003 viruses have 4 identical amino acid substitutions compared with the sequence of the parent SA14 virus at position E107, E138, E176 and E279. Of those the amino acids at position E138 and E176 (Ni, H. et al. JGen Virol. 76:409-413, 1995), which were known to contribute to attenuation were still conserved after Vero adaptation, suggesting that CJ50003 did not lose it's attenuated character.
-9k
Figure imgf000018_0001
εooosiD PUB χαd)z-M-wvs
Figure imgf000018_0002
Ηvs
'surejjs sruiΛ grj guoure ssousnbos pps OUΓUIB puB spμospnu o
Figure imgf000018_0003
3|qB
S^00/86M /X3c[ Z9Z,IΪ/660Λ CJ50003 and the parent SA14-14-2(PDK) were tested for their mice neurovirulence by intracerebral (i.e.) injection into the 4-week-old BALB/c mice. The results are shown in Table 2. The lethality for young adult mice is not significantly different between SA14-14-2(PDK) and CJ50003 viruses which is very low compared to that of wild type SA14 virus. Thus it seems to be that the introduction to the Vero cell substrate did not provide a neuro virulent phenotype to the SA14-14-2(PDK) and CJ50003 virus still has attenuated character.
Table 2. Intracerebral virulence of 4-week-old mice inoculated with Vero-passaged CJ50O03 viruses. PS represents passage in PDK or Vero cell.
Virus PFU Inoculum log LD50m ' LD50/PFU ratio
SA14(PDK, PS3) 2 x 10(7) 6.5 0.1 T
SA14-14-2(PDK,PS8) 1.3 x 10(6) <1.5b <0.00002a
CJ50003(Vero, PS6) 3.4 x 10(7) <1.5b O.000001
CJ50003(Vero, PS15) 3.2 x 10(7) <1.5b O.000001
CJ50003(Vero, PS30) 3.6 x 10(7) <1.5b O.000001 a: Kenneth H. Eckels et al (Vaccine 6:513-518, 1988). b: 0/10 mice died after inoculation with undiluted virus.
The volume of inoculum for i.e. injection is 0.03 ml per mouse.
EXAMPLE 3
Virus growth and purification
The production seed was prepared in virus passage 5 in Vero cell [CJ50003 (Vero, PS5)]and stored in deep-freezer. Vero cells were grown in Eagle's minimal essential medium (EMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco). Roller bottle cultures of Vero cell monolayers were infected with production seed virus at an moi of 0.01 to 0.1 pfu per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM not containing serum and incubated at 35°C. In infected Vero cell cultures, virus reached titers of around 107 to 108 pfu/ml at
2 or 3 days post infection. While virus harvests were taken 4 times at 2 day intervals until 8 or 9 days post infection starting from 2 or 3 days post infection, virus titers were still maintained over 107 pfu/ml with very weak CPE. But after 9 days post infection, the titers were under 107 pfu/ml (Figure 2). The pooled harvests were centrifuged at 8,000 rpm for 15 minutes and supernatants were filtered through a 0.45 μm filter. Virus culture supernatants were concentrated by ultrafiltration (Ultrasette, Filtron, 100k) or precipitation with PEG. The virus precipitated by PEG was collected by centrifugation and suspended in PBS or STE (10 mM Tris pH 7.2, 1 mM EDTA, 150 mM NaCl) buffer. Retentate after ultrafiltration was concentrated to 250 ml and the cassette was washed with 100 ml of PBS. Virus concentrates were chilled in the ice for 2 hours after adding 0.5 -2 mg/ml of protamine sulfate and the supernatants obtained by centrifuging at 10,000 rpm for 5 minutes. The concentrated viruses were purified by ultracentrifugation on sucrose gradients. The ultracentrifugation was carried out at 38,000 g for 18 hours. Fractions were subjected to electrophoresis on polyacrylamide gels containing the detergent sodium dodecyl sulfate (SDS-PAGE). The nucleocapsid protein (C, 13,500 Da), membrane protein (M, 8,700 Da) and envelope protein (E,
53,000 Da) bands were seen in the SDS-PAGE (Figure 3, panel A). Envelope antigens (E) were detected by Western blotting with mouse anti-JE virus monoclonal antibody (Figure 3, panel C). Virus positive fractions, fraction Nos.4 to 9, in which other protein bands except viral proteins were not apparent in silver stained gel (Figure 3, panel B) were pooled, and assayed for protein concentration by Lowry method. Detailed results are shown from two purifications from infected Vero cultures either concentrated with tangential flow ultrafiltration or by PEG8000 precipitation (Tables 3 and 4). Purified virus was diluted with two volumes of PBS, added to the final 0.01% of Tween80, and filtered through a 0.22 μm filter.
Table 3. Purification of JE virus by concentration with tangential flow ultrafiltration.
Figure imgf000020_0001
Pooled culture
10,000 4.4x10" 100 600 100 7.3xl07 supernatant Filtron
200 4.0x10" 90 280 47 1.4x10s concentrate
Sucrose gradient
500 3.8x10" 86 42 7 9.0xl09 pool
0.22 μ filtration 50 2.4x10" 55 23 3.8 1.0x10'°
Table 4. Purification of JE virus by concentration with PEG8000 precipitation.
Figure imgf000021_0001
Pooled culture
10,000 4.4x10" 100 600 100 7.3x107 supernatant
PEC precipitate 200 2.7x10" 61 40 6.7 6.8xl09
Sucrose gradient
500 2.5x10" 56 15 2.5 1.7x10'° pool
0.22 μ filtration 50 1.6x10" 41 12 2 1.3xl010
The virus preparations were compared for relative purity using specific activity measurements (i.e., pfu/mg protein). Virus purified from concentrate by ultrafiltration had about the same activity as virus purified from concentrate by PEG8000 precipitation. Also the purity of the pooled purified viruses was estimated by testing for Vero cell originated chromosomal DNA and protein. The results showed that contents of host cellular DNA and protein are as low as 2.5 pg and 2 ng per 5 μg of purified JE virus respectively regardless of method of concentration, which demonstrated that both purification methods described above effectively removed other impurities from viral antigen. However in terms of protein yield of purified virus, the purification method using ultrafiltration is 2-fold better than the purification method involving PEG8000 precipitation.
EXAMPLE 4 Virus inactivation Purified virus was either directly used for preparation of live attenuated vaccine after dialysis with PBS or inactivated with formaldehyde for preparation of inactivated vaccine. Inactivation with 0.018% formaldehyde was carried out at 22°C or 4°C. Samples were taken at regular intervals and assayed directly for infectious virus by plaque titration (Figure 4). Samples which were negative by direct plaque assay were subjected to blind passage on Vero cell monolayers in order to amplify low levels of virus and then re-plaqued. It was found that 4 days at 22°C or 46 days at 4°C were required for complete inactivation of infectivity (Tables 5 and 6). The antigenicity of the virus was monitored during inactivation by testing samples with the antigen spot blot assay and polyclonal antisera. By this assay there appeared to be no detectable losses in antigenicity after exposure to 0.018% formaldehyde for up to 10 days at 22°C or 15 days at 4°C.
Inactivation with formaldehyde under these conditions was carried out for at least 7 days at 22°C or 60 days at 4°C, giving a margin of safety. After inactivation, free formaldehyde in the samples was neutralized by the addition of 0.038% of sodium metabisulfite. Dialysis was carried out concurrently with PBS and then filtered through a 0.22 μm filter.
Table 5. Formaldehyde inactivation of JE virus, CJ50003 at 4°C
Day JE virus (-HCHO) JE virus (+HCHO) Amplification
0 3.2 x lO8 3.2 x lO8 +
0.5 2.6 x lO8 3.2 x lO6 +
1 1.52 x lO8 7.9 x lO5 +
1.5 2.4 x lO8 4.8 x lO5 +
2 2.8 x lO8 6.4 x lO4 +
3 2.6 x lO8 4.3 x lO3 +
4 1.9 x l08 1300 +
5 2.4 x lO8 285 +
6 2.8 x lO8 480 + 7 1.5 x lO8 200 +
11 1.5 x lO8 0 +
22 1.4 x lO8 0 +
32 1.2 x lO8 0 +
46 1.0 x lO8 0 -
60 1.0 x lO8 0 -
Table 6. Formaldehyde inactivation of JE virus at 22°C
Hour JE virus (-HCHO) JE virus (+HCHO) Amplification
0 3.2 x lO8 3.2 x lO8 +
3 3.0 x lO8 1.3 x lO6 +
6 2.7 x lO8 1.1 x 10s +
12 2.5 x lO8 3.5 x 105 +
24 1.2 x lO8 140 +
36 1.2 x lO8 0 +
48 1.2 x lO8 0 +
72 1.1 x lO8 0 +
96 1.1 x lO8 0 -
360 1.0 x lO8 0 -
EXAMPLE 5
Immunogenicity of CJ50003 purified, inactivated virus (PIV) and live attenuated virus (LAV) in mice
The immunogenicities of LAV and PIV were then tested in mice with previously commercialized Biken inactivated vaccine. Groups of 20 six-week-old BALB/c mice were immunized intraperitoneally (i.p.) with three kinds of immunogen. Immunization was done with two inoculations without an adjuvant at intervals of 2 weeks. Two weeks post second immunization sera were obtained from each group of mice, pooled and subsequently tested for the presence of neutralizing antibodies by PRNT method (Table 7). As shown in Table 7, there was no significant difference in neutralizing antibody titer between groups which received three kinds of immunogen.
Table 7. Induction of neutralizing antibodies in mice immunized with PIV or LAV Immunogen Dose Titers of neutralizing antibodies a
PIV 5 g 1 :320
PΓV 10 μg 1 :320
LAV 5 μg 1 :320
LAV 10 g 1: 640
BBiikkeenn vvaacccciinnee b 11 ddoossee 1: 320 a: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques . b: Biken vaccine 1 dose contains 5 μg of viral protein (TCA-precipitable) according to the manufacturer.
The Immunogenicity of PIV was further tested in mice. Adult, inbred mice were immunized with various dilutions of inactivated virus with or without an alum adjuvant. Groups of 20 six-week-old BALB/c mice were immunized subcutaneously with 500, 50, and 5 ng of PIV either in saline or saline with aluminum hydroxide (Rehydragel). Mice received two inoculations spaced 3 weeks apart. Sera were pooled from each group of mice at 3 weeks post second immunization, and tested for the presence of neutralizing antibodies with mouse brain passaged Nakayana strain as neutralized virus (Table 8). PIV was better than Biken vaccine in all doses and adjuvant significantly improved the immune response of mice to 50 and 500 ng of PIV about 4 and 8 fold, respectively.
Table 8. Comparison of the titer of neutralizing antibody in mice immunized with PIV with or without alum hydroxide.
Titers of Immunogen Dose neutralizing antibodies a PIV 500 ng 1 :160
PIV 50 ng 1 :40
PIV 5 ng 1:20
PIV + alum 500 ng 1 : 1280
PIV + alum 50 ng 1 : 160
PIV + alum 5 ng 1 : 20
Biken vaccine 1/10 dose 1: 80
Biken vaccine 1/100 dose 1 : 10
Biken vaccine 1/1000 dose 1: 10 a: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques, b: Biken vaccine 1 dose contains 5 μg of viral protein (TCA-precipi table) according to the manufacturer.
The in vivo protective efficacy of PIV was then tested in BALB/c mice. For protection assays, groups of 10 three- week-old BALB/c mice were inoculated subcutaneously in the hindquarters with inactivated JE viruses in saline or saline with aluminum hydroxide (Rehydragel). Age-matched controls were inoculated with PBS or non-specific antigens in alum. Mice were boosted with an equivalent dose three weeks later. The mice were challenged at 3 weeks post immunization by intracranial inoculation with 500 pfu of the mouse neurovirulent JE virus (Nakayama, mouse brain adapted) contained in 30 μl of PBS. Challenged mice were monitored daily for morbidity and mortality for up to twenty-one days. As shown in Table 9, mice immunized with 50 ng of PIV showed 90% of protection. Furthermore, mice immunized with 50 and 5 ng of PIV mixed with alum showed 100% and 70% protection, respectively while 1/100 dose of Biken vaccine protected just 50% of immunized mice. In comparison, all mice in the control group became sick and died beginning at five to seven days post-challenge. Table 9. Protection of vaccinated mice against challenge with Nakayama virus3 Immunogen
Immunogen Dose Survivors
Control b N/A 0/10
PIV 500 ng 10/10
PIV 50 ng 9/10
PIV 5 ng 3/10
PIV + alum 500 ng 10/10
PIV + alum 50 ng 10/10
PIV + alum 5 ng 7/10
Biken vaccine c 1/10 dose 10/10
Biken vaccine 1/100 dose 5/10
Biken vaccine 1/1000 dose 3/10 a: Mice immunized with 2 inoculations of test vaccines spaced 3 weeks apart, then challenged with 500 pfu of mouse-neuro virulent Nakayama virus, b: Age-matched controls were inoculated with PBS or non-specific antigens in alum c: Biken vaccine 1 dose contains 5 μg of viral protein (TCA-precipitable) according to the manufacturer .
To investigate immunologic stability of CJ50003 virus over Vero cell passages, viruses with various passage numbers in Vero cell were independently purified and the immunogenicities were evaluated by the method as described in Table 8. As shown in Table 10, there was no remarkable difference in the ability to elicit neutralizing antibodies among vaccines prepared from the viruses with different virus passage numbers in Vero cell, indicating that CJ50003 virus is very stable over Vero cell passages in terms of immunogenicity. Table 10. Vaccine potencies prepared with JE viruses with different virus passage numbers in Vero cells
Titers of neutralizing
Immunogen a Dose S.d.c antibodiesb
PIV - 4ps 0.5 μg 1:150 20
PIV - 6ps 0.5 μg 1 :145 15
PIV - 15ps 0.5 μg 1:130 28
PIN - 20ps 0.5 μg 1 :140 18
PIV - 30ps 0.5 μg 1:160 13 a: Immunogen (PIV -Xps); purified inactivated vaccine prepared with CJ50003 virus of which passage number in Vero cells is X. b: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques and mean values of results from three separate experiments ere taken. 50% endpoint is determined by Reed and Muench method. c: Standard deviation
The results presented here suggest that both an inactivated JE virus vaccine and live attenuated vaccine using CJ50003 strain show promise. Relatively fast and efficient processes were developed for growing JE virus in Vero cell, concentrating and purifying them to a degree which may be suitable for human use and inactivating them without measurable loss in antigenicity. These preparations were found to be immunogenic and protective in mice.

Claims

WHAT IS CLAIMED IS:
1. An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.
2. The attenuated Japanese encephalitis virus according to claim 1 characterized in that multiplicity is more than 1x10(7) PFU/ml in Vero cells and LD50/pfu for young adult mouse is less than 0.000001.
3. The attenuated Japanese encephalitis virus according to claims 1 or 2 wherein is
CJ50003.
4. A Japanese encephalitis vaccine comprising the attenuated Japanese encephalitis virus according to claim 1.
5. The vaccine according to claim 4 wherein the virus is inactivated by an inactivating agent.
6. The vaccine according to claim 4 wherein the virus is live-attenuated JE virus untreated by an inactivating agent.
7. The vaccine according to claims 4, 5 or 6 which further comprises pharmaceutically acceptable additives.
PCT/KR1998/000259 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine WO1999011762A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE122009000037C DE122009000037I2 (en) 1997-08-28 1998-08-25 AN ANALYZED APPROVED JAPANESE ENZEPHALITIS VIRUS TO VERO CELLS AND A VACCINE AGAINST JAPANESE ENZEPHALITIS
DE69837211T DE69837211T2 (en) 1997-08-28 1998-08-25 AN APPROVED VERO CELLS JAPANESE ENZEPHALITIS VIRUS AND A VACCINATE AGAINST JAPANESE ENZEPHALITIS
JP2000508774A JP4161017B2 (en) 1997-08-28 1998-08-25 Attenuated Japanese encephalitis virus and Japanese encephalitis vaccine adapted to Vero cells
AU90047/98A AU748730B2 (en) 1997-08-28 1998-08-25 An attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine
CA002301000A CA2301000C (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
NZ503522A NZ503522A (en) 1997-08-28 1998-08-25 Attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine
US09/486,392 US6309650B1 (en) 1997-08-28 1998-08-25 Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
DK98941885T DK1025209T3 (en) 1997-08-28 1998-08-25 An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
EP98941885A EP1025209B1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
NL300391C NL300391I2 (en) 1997-08-28 2009-06-10 A weakened Japanese encephalitis virus adapted to Vero cells and a Japanese encephalitis vaccine
FR09C0037C FR09C0037I2 (en) 1997-08-28 2009-08-14 ATTENUATED, VERO CELL-ADAPTED JAPANESE ENCEPHALITIS VIRUS AND JAPANESE ENCEPHALITIS VACCINE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR1997/42001 1997-08-28
KR1997/42002 1997-08-28
KR19970042001 1997-08-28

Publications (1)

Publication Number Publication Date
WO1999011762A1 true WO1999011762A1 (en) 1999-03-11

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Country Status (15)

Country Link
US (1) US6309650B1 (en)
EP (2) EP1025209B1 (en)
JP (1) JP4161017B2 (en)
KR (1) KR100314404B1 (en)
CN (1) CN1142271C (en)
AU (1) AU748730B2 (en)
CA (1) CA2301000C (en)
DE (2) DE122009000037I2 (en)
DK (2) DK1025209T3 (en)
ES (2) ES2281929T3 (en)
FR (1) FR09C0037I2 (en)
MY (1) MY129773A (en)
NL (1) NL300391I2 (en)
NZ (1) NZ503522A (en)
WO (1) WO1999011762A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1057889A1 (en) * 1998-10-05 2000-12-06 The Research Foundation for Microbial Diseases of Osaka University Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
JP2003523727A (en) * 1999-04-22 2003-08-12 ユナイテッド ステイツ デパートメント オブ アグリカルチャー Porcine (porcelain) reproduction and respiratory syndrome vaccine based on isolated JA-142
WO2009082002A1 (en) * 2007-12-26 2009-07-02 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2298344A1 (en) * 2008-06-04 2011-03-23 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
WO2010137036A3 (en) * 2009-05-25 2011-05-26 Panacea Biotec Ltd Japanese encephalitis vaccine and method of manufacturing the same
WO2015059714A1 (en) * 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
US10537630B2 (en) 2015-12-23 2020-01-21 Valneva Se Virus purification
US10881723B2 (en) 2016-01-15 2021-01-05 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
US11357846B2 (en) 2017-09-21 2022-06-14 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Delta5NP3
US11478541B2 (en) 2017-11-03 2022-10-25 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
US11975062B2 (en) 2017-11-30 2024-05-07 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (en) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst Japanese encephalitis virus vaccine
CN1253220C (en) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (en) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst West nile virus vaccine
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CN100340596C (en) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 Recovery of polycarbonate / acrylonitrile-butadiene-styrene copolymer and method for reclaiming same
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co Flavivirus vaccine vector against influenza virus
JP5744517B2 (en) * 2008-07-30 2015-07-08 久光製薬株式会社 Microneedle device and method for increasing the efficacy of Japanese encephalitis virus antigen by microneedle device
KR101144993B1 (en) * 2009-06-18 2012-06-27 대한민국 Antigen for high concentrated hemagglutination of porcine japanese encephalitis virus
DK3785730T3 (en) 2011-12-06 2024-05-06 Valneva Austria Gmbh ALUMINUM COMPOUNDS FOR USE IN THERAPEUTIC PRODUCTS AND VACCINES
CN105695424B (en) * 2015-04-01 2019-06-14 中国食品药品检定研究院 Adapted strain and its vaccine of the Japanese Encephalitis Vaccine,Live strain SA14-14-2 on human diploid cell 2BS
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
CN110684747B (en) * 2018-07-06 2024-05-24 厦门大学 Method for inactivating and preserving respiratory syncytial virus
JP7376013B2 (en) * 2018-08-27 2023-11-08 マイキャン・テクノロジーズ株式会社 Evaluation method for anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01117780A (en) * 1987-10-31 1989-05-10 Nippon Zoki Pharmaceut Co Ltd Recombinant vaccinia virus
JPH02223531A (en) * 1988-11-10 1990-09-05 Takeda Chem Ind Ltd Vaccine of japanese encephalitis and production thereof
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01117780A (en) * 1987-10-31 1989-05-10 Nippon Zoki Pharmaceut Co Ltd Recombinant vaccinia virus
JPH02223531A (en) * 1988-11-10 1990-09-05 Takeda Chem Ind Ltd Vaccine of japanese encephalitis and production thereof
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Vol. 13, No. 339, 1989; & JP,A,01 117 780 (NIPPON ZOKI PHARMACEUT CO., LTD.) 31 July 1989. *
PATENT ABSTRACTS OF JAPAN, Vol. 14, No. 535, 1990; & JP,A,02 223 531 (TEKADA CHEM. IND., LTD.) 26 November 1990. *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1057889A4 (en) * 1998-10-05 2002-01-23 Univ Osaka Res Found Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
US6841374B1 (en) 1998-10-05 2005-01-11 Research Foundation For Microbial Diseases Of Osaka University Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
EP1057889A1 (en) * 1998-10-05 2000-12-06 The Research Foundation for Microbial Diseases of Osaka University Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
JP2003523727A (en) * 1999-04-22 2003-08-12 ユナイテッド ステイツ デパートメント オブ アグリカルチャー Porcine (porcelain) reproduction and respiratory syndrome vaccine based on isolated JA-142
JP4778620B2 (en) * 1999-04-22 2011-09-21 ユナイテッド ステイツ デパートメント オブ アグリカルチャー Pig breeding / breathing disorder syndrome vaccine based on isolate JA-142
JP2010239973A (en) * 1999-04-22 2010-10-28 United States Department Of Agriculture Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
JP4751558B2 (en) * 2000-04-07 2011-08-17 一般財団法人化学及血清療法研究所 Japanese encephalitis inactivated vaccine and production method thereof
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
WO2009082002A1 (en) * 2007-12-26 2009-07-02 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2233151A1 (en) * 2007-12-26 2010-09-29 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2233151A4 (en) * 2007-12-26 2012-02-08 Kitasato Inst Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
AU2008342194B2 (en) * 2007-12-26 2014-03-20 Daiichi Sankyo Company, Limited Method of producing Japanese encephalitis vaccine stably storable over long time and use of the vaccine
US9453055B2 (en) 2007-12-26 2016-09-27 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2298344A1 (en) * 2008-06-04 2011-03-23 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
EP2298344A4 (en) * 2008-06-04 2013-04-24 Chemo Sero Therapeut Res Inst Use of inactivated japanese encephalitis virus particle as adjuvant
US9114098B2 (en) 2008-06-04 2015-08-25 The Chemo-Sero-Therapeutic Research Institute Method for using inactivated Japanese encephalitis virus particles as adjuvant
WO2010137036A3 (en) * 2009-05-25 2011-05-26 Panacea Biotec Ltd Japanese encephalitis vaccine and method of manufacturing the same
WO2015059714A1 (en) * 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
RU2706693C2 (en) * 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Virus vaccine and methods for production thereof
AU2014338520B2 (en) * 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
US10660950B2 (en) 2015-12-23 2020-05-26 Valneva Se Virus purification
EP4218807A2 (en) 2015-12-23 2023-08-02 Valneva Austria GmbH Zika virus vaccine
US10537630B2 (en) 2015-12-23 2020-01-21 Valneva Se Virus purification
US10744194B2 (en) 2015-12-23 2020-08-18 Valneva Austria Gmbh Zika virus purification
US12005111B2 (en) 2015-12-23 2024-06-11 Valneva Austria Gmbh Zika virus vaccine
US11207397B2 (en) 2015-12-23 2021-12-28 Valneva Se Virus purification
US11219681B2 (en) 2015-12-23 2022-01-11 Valneva Austria Gmbh Zika virus vaccine
US11331382B2 (en) 2015-12-23 2022-05-17 Valneva Austria Gmbh Zika virus purification
EP4357355A2 (en) 2015-12-23 2024-04-24 Valneva SE Virus purification
US11406700B2 (en) 2015-12-23 2022-08-09 Valneva Se Virus purification
US11951163B2 (en) 2015-12-23 2024-04-09 Valneva Austria Gmbh Zika virus vaccine
US10639365B2 (en) 2015-12-23 2020-05-05 Valneva Austria Gmbh Zika virus vaccine
US11524064B2 (en) 2015-12-23 2022-12-13 Valneva Austria Gmbh Zika virus purification
TWI781700B (en) * 2016-01-15 2022-10-21 日商Ｋｍ生物醫藥股份有限公司 Method for producing immobilized virus particles and method for producing vaccine
TWI781088B (en) * 2016-01-15 2022-10-21 日商Ｋｍ生物醫藥股份有限公司 Vaccines containing immobilized virions
US10881723B2 (en) 2016-01-15 2021-01-05 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
US11484587B2 (en) 2017-09-21 2022-11-01 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
US11357846B2 (en) 2017-09-21 2022-06-14 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Delta5NP3
US12011477B2 (en) 2017-09-21 2024-06-18 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
US11478541B2 (en) 2017-11-03 2022-10-25 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US11730802B2 (en) 2017-11-03 2023-08-22 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US11964008B2 (en) 2017-11-03 2024-04-23 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
US11975062B2 (en) 2017-11-30 2024-05-07 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Also Published As

Publication number Publication date
CA2301000A1 (en) 1999-03-11
EP1025209B1 (en) 2007-02-28
DE69837211T2 (en) 2007-12-06
ES2281929T3 (en) 2007-10-01
EP1604685B1 (en) 2012-02-22
EP1604685A2 (en) 2005-12-14
DE122009000037I1 (en) 2009-11-05
AU748730B2 (en) 2002-06-13
JP2001514844A (en) 2001-09-18
DE69837211D1 (en) 2007-04-12
NZ503522A (en) 2001-06-29
FR09C0037I1 (en) 2009-09-25
CN1142271C (en) 2004-03-17
AU9004798A (en) 1999-03-22
DE122009000037I2 (en) 2011-06-16
CN1272879A (en) 2000-11-08
NL300391I1 (en) 2009-08-03
US6309650B1 (en) 2001-10-30
DK1025209T3 (en) 2007-06-25
KR100314404B1 (en) 2002-10-12
NL300391I2 (en) 2009-11-02
KR19990023955A (en) 1999-03-25
FR09C0037I2 (en) 2021-11-05
MY129773A (en) 2007-04-30
DK1604685T3 (en) 2012-06-18
CA2301000C (en) 2003-07-08
EP1025209A1 (en) 2000-08-09
ES2382946T3 (en) 2012-06-14
EP1604685A3 (en) 2006-07-05
JP4161017B2 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
AU748730B2 (en) An attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine
US10548964B2 (en) Antigens and vaccines directed against human enteroviruses
CN108601825B (en) Vaccine composition
JP5095685B2 (en) Enhanced immunogen for inactivated vaccine against Japanese encephalitis virus group infection and method for producing the same
US20150056244A1 (en) Antigens and Vaccines Directed Against Human Enteroviruses
EP2459709A2 (en) High yield yellow fever virus strain with increased propagation in cells
CN110734500A (en) Methods and compositions for dengue virus vaccines
CN113186171B (en) Attenuated virus of flavivirus and application thereof
TWI228147B (en) An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98809797.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2301000

Country of ref document: CA

Ref document number: 2301000

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998941885

Country of ref document: EP

Ref document number: 1200000166

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 503522

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 90047/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09486392

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998941885

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 90047/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998941885

Country of ref document: EP